23 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists.
Dainippon Sumitomo Pharma
The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.
Merck Research Laboratories
Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes.
Merck Research Laboratories
A new approach to search for the bioactive conformation of glucagon: positional cyclization scanning.
University of Arizona
Design and synthesis of conformationally constrained glucagon analogues.
University of Arizona
The role of phenylalanine at position 6 in glucagon's mechanism of biological action: multiple replacement analogues of glucagon.
University of Arizona
Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.
University of Arizona
Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.
Merck Research Laboratories
Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.
Novo Nordisk
New beta-alanine derivatives are orally available glucagon receptor antagonists.
Novo Nordisk
A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice.
Beijing University of Chinese Medicine
Current anti-diabetic agents and their molecular targets: A review.
University of Kwazulu-Natal
Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists.
Indiana University
Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.
Novo Nordisk
Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.
Syracuse University
Optimization of peptide-based polyagonists for treatment of diabetes and obesity.
Novo Nordisk Research Center Indianapolis